The Herbal Cocktail GSYJ Attenuated Airway Inflammatory Cell Infiltration in a Chronic Asthmatic Mouse Model.

Chung-Jen Chiang,Li-Jen Lin,Shu-Lun Chang,Jun-Yong Choi

doi:10.1155/2021/6691475

Abstract

This study explored the potential therapeutic efficacy of GSYJ in attenuating asthma symptom severity and aimed to determine the immunomodulatory mechanism of GSYJ. A mouse model of chronic asthma induced by repeated Dermatophagoides pteronyssinus (Der p) challenge was established. In addition, 30 minutes before Der p challenge, the mice were orally administered GSYJ (1 g/kg). The mice were sacrificed to evaluate inflammatory cell infiltration, collagen deposition in the lung, total IgE in serum, and expression profiles of various cytokines in bronchoalveolar lavage fluid (BALF) and various genes in lung tissue. Furthermore, 30 minutes after the addition of GSYJ to RAW264.7 cell cultures, 100 ng/ml LPS was added to evaluate the effect of the drug on the LPS-induced expression of genes, proteins, and transcription factors. GSYJ may regulate transcription factors (cJUN/IRF3/NF-κB) to decrease the expression of IL-1β, IL-6, RANTES, and iNOS in macrophages and affect the IL-12, IFN-γ, IL-5, and IL-6 levels in the BALF of mice to relieve asthma symptoms, such as inflammatory cell infiltration, hyperresponsiveness, and increased serum total IgE levels. Therefore, GSYJ has the potential to be developed into a drug treatment for chronic asthma.

Highlights

Asthma is characterized by chronic inflammation, airway hyperresponsiveness (AHR), and mucus secretion [1, 2]
We tested the effects of GSYJ on AHR and inflammation in a repetitive Dermatophagoides pteronyssinus (Der p) challenge model
GSYJ inhibits the expression of the IL-1β, IL-6, RANTES, and inducible nitric oxide synthase (iNOS) mRNAs in LPS-induced macrophages. erefore, we examined whether GSYJ inhibited the expression of these genes by regulating the transcription factors JUN, IRF3, and p65

Summary

Introduction

Asthma is characterized by chronic inflammation, airway hyperresponsiveness (AHR), and mucus secretion [1, 2]. 300 million people have asthma in the world, resulting in spending of billions of dollars in healthcare [3]. 53% of patients with asthma had a history of asthma attacks in the previous year, and 42% of patients had not attended school for more than one day or had not worked for a period of time due to worsening symptoms [4]. Effective asthma prevention strategies or known cures are not available [5, 6]. When inhaled corticosteroid use is discontinued, the effects on asthma rapidly disappear [6]. Inhaled corticosteroids often decrease asthma-related mortality, the prevalence of asthma is still increasing [8]. New asthma drugs are needed to overcome the limitations of current treatments

Methods

Results

Discussion

Conclusion